Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (NCT06268886)

🧪 Interventions in This Study

• BMS-986446 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (176 Sites)

Showing the first 25 of 176 sites.

• Local Institution - 0068 — Chandler, Arizona
• Local Institution - 0102 — Gilbert, Arizona
• Local Institution - 0019 — Phoenix, Arizona
• Local Institution - 0018 — Scottsdale, Arizona
• Local Institution - 0026 — Scottsdale, Arizona
• Local Institution - 0077 — Tucson, Arizona
• Local Institution - 0038 — Tucson, Arizona
• Local Institution - 0164 — Encino, California
• Local Institution - 0139 — Fullerton, California
• Local Institution - 0191 — Irvine, California
• Local Institution - 0234 — Long Beach, California
• Local Institution - 0142 — Los Alamitos, California
• Local Institution - 0037 — Napa, California
• Local Institution - 0209 — Sacramento, California
• Local Institution - 0052 — San Francisco, California
• Local Institution - 0137 — Santa Ana, California
• Local Institution - 0046 — Sherman Oaks, California
• Local Institution - 0106 — Danbury, Connecticut
• Local Institution - 0148 — New Haven, Connecticut
• Local Institution - 0056 — New Haven, Connecticut
• Local Institution - 0153 — Stamford, Connecticut
• Local Institution - 0022 — Altamonte Springs, Florida
• Local Institution - 0048 — Atlantis, Florida
• Local Institution - 0228 — Boca Raton, Florida
• Local Institution - 0250 — Boca Raton, Florida

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Alzheimer Disease, Early Onset

• Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study — Winston-Salem, North Carolina
• Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease — Baltimore, Maryland
• PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) — Irvine, California
• Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau — New York, New York
• Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD — Los Angeles, California

Explore by condition: All Alzheimer Disease, Early Onset clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.